This inventor holds 5 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: University of Regensburg, Zentaris Ag, Friedrich-Schiller-Universitat Jena. Active years: 2002-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 14 
2 out of 20 
1 out of 27 Years Active: 2002-2022
Title: Siavosh Mahboobi: Innovator in Cancer Treatment
Introduction
Siavosh Mahboobi is a prominent inventor based in Wuppertal, Germany. With a remarkable portfolio of five patents, he has significantly contributed to the field of cancer treatment and pharmacology. His innovative work focuses on developing small molecule compounds aimed at addressing critical medical challenges.
Latest Patents
Among his patents, Siavosh Mahboobi’s latest contributions include the synthesis, pharmacology, and application of new and selective FLT3 inhibitors. This invention relates to small molecule compounds designed for the treatment of diseases such as acute myeloid leukemia (AML). Additionally, he has developed HDAC6 inhibitors with improved solubility, which are intended for use in cancer treatment. These compounds offer enhanced pharmaceutical properties through the introduction of basic substituents while also detailing methods for synthesis and treatment applications.
Career Highlights
Siavosh Mahboobi has a strong professional background, having worked with esteemed institutions. Notably, he has been associated with the University of Regensburg and Zentaris AG. His tenure at these organizations has allowed him to push the boundaries of research and innovation.
Collaborations
Throughout his career, Siavosh has collaborated with notable colleagues, including Herwig Pongratz and Sabine Kuhr. These partnerships have contributed to the successful development of his patented compounds and furthered advancements in cancer research.
Conclusion
Siavosh Mahboobi's contributions to science and medicine highlight the importance of innovation in the treatment of severe diseases like cancer. His patents not only demonstrate his commitment to developing effective therapeutic options but also reflect his collaborative spirit within the scientific community. As research continues to evolve, the impact of his work will likely be felt for years to come.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile